Retatrutide Research: What Do Clinical Studies Show in 2026?

Retatrutide has emerged as one of the most highly anticipated substances in metabolic studies in 2026. The reason for the high level of interest lies in the unique mechanism of action of retatrutide, which suggests that Retatrutide agonizes three receptors: the GIP receptor, GLP-1 receptor, and glucagon receptor.

In this well researched blog, we will dig deeper to learn about the historical research data and the latest research data recently published by Eli Lilly.

There are a number of clinical trials that have shown significant decreases in body weight, along with improvements in glucose metabolism. These results have been found in Phase 2 trials as well as Phase 3 top-line trials. Nonetheless, retatrutide still remains an investigational drug, and the results of some Phase 3 trials, being the latest ones, have only been published by the company as the topline data.

You can buy research grade retatrutide for clinical, lab or research studies at Neuro Peptides.

What is Retatrutide?

Retatrutide, also known as LY3437943, is an experimental peptide that stimulates the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

According to Coskun et al. LY3437943 is a unique compound with activity at the three systems of receptors, laying the scientific foundation for researching retatrutide as a triple hormone receptor agonist. Preclinical studies and initial clinical data were used by them to characterize the drug pharmacologically.

The concept of this drug is the merging of multiple metabolic signals in one molecule. GIP and GLP-1 regulate glucose and appetite signaling, respectively, while glucagon is responsible for energy metabolism. That is why clinicians examine this combination as a potential tool for producing an effect on body weight.

What Did the First Major Obesity Trial Show?

A significant amount of research on retatrutide has been performed as part of the obesity trial Phase 2 study published in the New England Journal of Medicine.

According to the study “Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial” retatrutide led to marked and dose-dependent body-weight reduction over 48 weeks in adults suffering from obesity.

Among patients receiving 12 mg of retatrutide once weekly, the average body-weight reduction was 24.2% in 48 weeks.

In contrast, for the placebo group, this figure was only -2.1%. Moreover, participants continued to lose weight up to the end of 48 weeks.

This study was important milestone as it offered some evidence that the triple-receptor method can lead to considerable weight reduction. Besides, the connection between dose and body-weight reduction also became apparent.

What Did the Type 2 Diabetes Study Find?

The efficacy of retatrutide has also been tested on individuals with type 2 diabetes mellitus.

According to Rosenstock et al., retatrutide treatment led to clinically meaningful improvement in glycemic control and significant weight loss in adults with type 2 diabetes mellitus.

Their Phase 2 study included a number of doses for 36 weeks and revealed that the impact on blood glucose and weight depended on the dose used. Also, according to the authors, the weight loss trend did not reach its plateau at the end of the study period.

This research also provided some valuable information concerning the safety issue.

According to Rosenstock et al., the safety profile turned out to be similar to that observed in the case of the use of GLP-1 receptor agonists and GIP/GLP-1 receptor agonists, with gastrointestinal disorders being among the most common adverse events.

These data became an important step in further development.

What Have Phase 3 Studies Shown?

The clinical evidence became even more significant in 2026. Eli Lilly has reported topline results from several Phase 3 trials in the TRIUMPH program.

In TRIUMPH-1, adults with obesity or overweight and at least one weight-related complication received different doses of retatrutide or placebo. Lilly reported that participants receiving 12 mg of retatrutide lost an average of 28.3% of their body weight at 80 weeks. The company also reported that 45.3% of participants receiving 12 mg achieved at least 30% weight loss.

These numbers are striking, but they need to be interpreted carefully. They are based on company-reported topline Phase 3 results. The complete trial findings, including detailed analyses and peer-reviewed publication, provide the fuller scientific picture.

The TRIUMPH-1 results also included changes in several cardiometabolic measures. Lilly reported improvements in waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein among participants receiving retatrutide.

What About Retatrutide in People with Type 2 Diabetes?

Another important question is whether the large weight reductions seen in obesity trials also occur in people with type 2 diabetes.

The answer from the available Phase 3 data appears encouraging.

Lilly reported that participants with obesity or overweight and type 2 diabetes in the TRIUMPH-2 trial lost up to an average of 20.8% of their body weight at 80 weeks with the 12-mg dose. The company also reported reductions in HbA1c, with the greatest dose producing an average reduction of up to 1.6 percentage points.

These findings build on the earlier Phase 2 results reported by Rosenstock et al. They suggest that retatrutide may affect both body weight and glucose regulation, although the long-term clinical significance still needs to be established through continued research.

What Did TRIUMPH-3 Investigate?

Retatrutide is also being studied in people who have obesity together with established cardiovascular disease.

TRIUMPH-3, according to ClinicalTrials.gov, is a randomized, double-blind Phase 3 study meant to evaluate the effectiveness and safety of once weekly retatrutide in participants with severe obesity and established cardiovascular disease. The primary outcome measure is percent change in body weight from baseline to Week 80.

This is an important research population. People with obesity and cardiovascular disease can have different medical risks from those in earlier obesity trials. Studying retatrutide in this group can therefore provide additional information about its potential role and safety.

Lilly reported that participants in TRIUMPH-3 receiving the highest dose achieved an average weight reduction of up to 22.6% at 80 weeks. The company released these findings as part of its July 2026 Phase 3 update.

What Side Effects Have Clinical Studies Reported?

Weight loss is only one part of clinical research. Researchers also need to understand how well participants tolerate a treatment.

Jastreboff et al. reported that gastrointestinal adverse events were the most common side effects in the Phase 2 obesity trial. Nausea, diarrhea, and vomiting were among the reported gastrointestinal events. The study also observed an increase in heart rate with retatrutide treatment.

The Phase 3 results have shown a broadly similar pattern.

Lilly reported nausea, diarrhea, constipation, and vomiting among the most frequently reported adverse events in TRIUMPH-1, with gastrointestinal events generally becoming more common at higher doses.

These findings are important because a compound’s clinical value depends on both its effectiveness and its tolerability. Large reductions in body weight must therefore be considered alongside the treatment’s safety profile.

What Do the Studies Tell Us Overall?

When the studies are viewed together, a fairly consistent picture emerges.

Jastreboff et al. showed substantial, dose-dependent weight loss in the Phase 2 obesity trial, with the highest dose producing a 24.2% mean reduction after 48 weeks.

Rosenstock et al. demonstrated that retatrutide could also improve glycemic control while reducing body weight in adults with type 2 diabetes.

The newer Phase 3 results have taken the findings further.

Lilly’s 2026 TRIUMPH results report average weight reductions approaching or exceeding 20% in several study populations, with the highest reported reduction reaching 28.3% in TRIUMPH-1 at 80 weeks.

Taken together, these findings explain why retatrutide has attracted so much attention in metabolic research. At the same time, it is important to distinguish established peer-reviewed evidence from newer company-reported results.

Is Retatrutide FDA Approved?

No. Retatrutide remains an investigational drug, and is not approved by the FDA for human consumption as of September 2026.

Eli Lilly states that retatrutide is an investigational once-weekly triple hormone receptor agonist and is currently being evaluated in clinical trials. The company has said that it plans to submit a Biologics License Application to the FDA in the first quarter of 2027.

This distinction is important for anyone researching retatrutide. Clinical trial findings apply to the investigational product used in those controlled studies. They should not automatically be applied to products sold outside clinical trials or assumed to have the same identity, purity, formulation, or safety profile.

FAQs

Q1. What have clinical studies shown about retatrutide?

Jastreboff et al. showed that retatrutide produced substantial dose-dependent weight loss in adults with obesity, including a 24.2% mean reduction at the 12-mg dose after 48 weeks. More recent Phase 3 topline results from Lilly reported an average reduction of 28.3% at 80 weeks with 12 mg in TRIUMPH-1.

Q2. Has retatrutide been studied in people with type 2 diabetes?

Yes. Rosenstock et al. found clinically meaningful improvements in glycemic control and substantial body-weight reductions in adults with type 2 diabetes during a Phase 2 trial. Lilly has since reported additional Phase 3 results from TRIUMPH-2 in this population.

Q3. What are the most common side effects reported in studies?

Jastreboff et al. reported gastrointestinal adverse events as the most common side effects in the Phase 2 obesity trial. Nausea, diarrhea, and vomiting were among the reported events. Lilly has reported a similar pattern in Phase 3, including nausea, diarrhea, constipation, and vomiting.

Q4. Is the 28.3% weight-loss figure from a clinical study?

Of course, it does matter whether the evidence is preliminary. Lilly claims that there is an average decrease of 28.3% in body weight after 80 weeks in the 12 mg TRIUMPH-1 cohort. It is important to note that the above statement is a Phase 3 topline data provided by the company.

Conclusion

The clinical research on retatrutide has moved a long way since the first Phase 2 trials.

Jastreboff et al. demonstrated substantial weight loss in adults with obesity, while Rosenstock et al. showed improvements in both glycemic control and body weight among adults with type 2 diabetes.

The 2026 Phase 3 results have added another layer of evidence. Lilly has reported weight reductions of up to 28.3% in TRIUMPH-1 and up to 20.8% in TRIUMPH-2, along with improvements in several metabolic measures.

The overall findings are promising, but retatrutide remains investigational. The most recent Phase 3 results should also be read with their current status in mind, since detailed peer-reviewed publications are still needed.

For researchers, the main takeaway is straightforward: clinical studies have produced strong evidence that retatrutide can substantially affect body weight and metabolic measures, but its full long-term safety, efficacy, and regulatory status are still being established.

References

1. Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., … & Milicevic, Z. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247.
2. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., … & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial. New England Journal of Medicine, 389(6), 514-526. 
3. Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., … & Coskun, T. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 402(10401), 529-544. 
4. Eli Lilly and Company. (2026, May 21). Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.
5. ClinicalTrials.gov. (2026). A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3), NCT05882045.
6. Eli Lilly and Company. (2026, July 23). Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C.
7. Eli Lilly and Company. (2026). What to know about retatrutide: An investigational triple hormone receptor agonist.